Gamida Cell has patented a method for expanding transplantable NK cell fractions for cancer treatment. The process involves culturing, supplementing, harvesting, washing, and concentrating the cells before storing for infusion into human subjects. The method aims to improve cell transplant and infusion outcomes for cancer and other diseases. GlobalData’s report on Gamida Cell gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Gamida Cell Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Gamida Cell, T-cell culturing was a key innovation area identified from patents. Gamida Cell's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11834677B2) discloses a method for preparing a transplantable NK cell fraction for transplantation into a human subject over 18 years of age. The method involves ex vivo culturing a CD3-depleted NK cell fraction under specific conditions, including the addition of nutrients, serum, IL-15, and nicotinamide. The cultured cells are then supplemented and harvested in two portions, with the first portion comprising about 50% of the expanded NK cell fraction. These portions are washed, concentrated, reconstituted, and stored at room temperature before infusion into the subject, ensuring specific parameters are met for cell viability and safety.

Furthermore, the method outlined in the patent specifies the requirements for the NK cell fraction, including HLA matching criteria, absence of recipient donor-specific anti-HLA antibodies, and a specific percentage of CD56+/CD3- cells. The washed and concentrated portions of the expanded NK cell fraction must meet certain parameters, such as cell composition, viability, and absence of contaminants, to ensure safe and effective transplantation. By following this method, researchers and healthcare professionals can prepare a transplantable NK cell fraction for therapeutic use in patients in need, adhering to strict guidelines for cell quality and safety.

To know more about GlobalData’s detailed insights on Gamida Cell, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies